FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia
August 17, 2017 -- The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
“For adult patients with B-cell...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news